Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2013, Article ID 169107, 10 pages
http://dx.doi.org/10.1155/2013/169107
Clinical Study

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia

1Vital Prospects Clinical Research Institute, PC, Tulsa, OK 74136, USA
2Luitpold Pharmaceuticals, Inc., Norristown, PA 19403, USA
3Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Received 29 May 2013; Revised 25 July 2013; Accepted 26 July 2013

Academic Editor: Aurelio Maggio

Copyright © 2013 Iftikhar Hussain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. A. Lyseng-Williamson and G. M. Keating, “Ferric carboxymaltose: a review of its use in iron-deficiency anaemia,” Drugs, vol. 69, no. 6, pp. 739–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. F. Clark, “Iron deficiency anemia: diagnosis and management,” Current Opinion in Gastroenterology, vol. 25, no. 2, pp. 122–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. Anonyme, “Ferric carboxymaltose: a breakthrough treatment for iron deficiency anaemia,” European Journal of Hospital Pharmacy Practice, vol. 15, pp. 62–65, 2009. View at Google Scholar
  4. D. B. Van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione, “Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial,” Obstetrics and Gynecology, vol. 110, no. 2 I, pp. 267–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. T. Goodnough, D. B. Van Wyck, A. Mangione, J. Morrison, P. E. Hadley, and J. A. Jehle, “Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial,” Transfusion, vol. 49, no. 12, pp. 2719–2728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Gasche, M. C. E. Lomer, I. Cavill, and G. Weiss, “Iron, anaemia, and inflammatory bowel diseases,” Gut, vol. 53, no. 8, pp. 1190–1197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. F. Clark, “Iron deficiency anemia,” Nutrition in Clinical Practice, vol. 23, no. 2, pp. 128–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. B. G. Danielson, P. Geisser, and W. Schneider, Iron Therapy with Special Emphasis on Intravenous Administration, Vifor (International) Inc., 1996.
  9. S. B. Silverstein, J. A. Gilreath, and G. M. Rodgers, “Intravenous iron therapy: a summary of treatment options and review of guidelines,” Journal of Pharmacy Practice, vol. 21, no. 6, pp. 431–443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Fishbane, V.-D. Ungureanu, J. K. Maesaka, C. J. Kaupke, V. Lim, and J. Wish, “The safety of intravenous iron dextran in hemodialysis patients,” American Journal of Kidney Diseases, vol. 28, no. 4, pp. 529–534, 1996. View at Google Scholar · View at Scopus
  11. D. B. Van Wyck, J. Anderson, and K. Johnson, “Labile iron in parenteral iron formulations: a quantitative and comparative study,” Nephrology Dialysis Transplantation, vol. 19, no. 3, pp. 561–565, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Santosh, P. Podaralla, and B. Miller, “Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol,” NDT Plus, vol. 3, no. 4, pp. 341–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Kulnigg, S. Stoinov, V. Simanenkov et al., “A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial,” American Journal of Gastroenterology, vol. 103, no. 5, pp. 1182–1192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Auerbach and H. Ballard, “Clinical use of intravenous iron: administration, efficacy, and safety,” Hematology/the Education Program of the American Society of Hematology, vol. 2010, pp. 338–347, 2010. View at Google Scholar · View at Scopus
  15. S. Tagboto, L. Cropper, J. Turner, and K. Pugh-Clarke, “The efficicacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients,” Journal of Renal Care, vol. 35, no. 1, pp. 18–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Ganzoni, “Total infusion of ferri-carbohydrate complexes,” Blut, vol. 25, pp. 349–351, 1972. View at Google Scholar
  17. P. W. F. Wilson, R. B. D'Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel, “Prediction of coronary heart disease using risk factor categories,” Circulation, vol. 97, no. 18, pp. 1837–1847, 1998. View at Google Scholar · View at Scopus
  18. Cancer Therapy Evaluation Program, “Common Terminology Criteria for Adverse Events, Version 3.0,” DCTD, NCI, NIH, DHHS March 2003, http://ctep.cancer.gov/.
  19. P. Geisser and J. Banké-Bochita, “Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia,” Arzneimittel-Forschung, vol. 60, no. 6 a, pp. 362–372, 2010. View at Google Scholar · View at Scopus
  20. G. Bailey, R. L. Strub, R. C. Klein, and J. Salvaggio, “Dextran-induced anaphylaxis,” Journal of the American Medical Association, vol. 200, no. 10, pp. 889–891, 1967. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Fishbane, “Safety in iron management,” American Journal of Kidney Diseases, vol. 41, no. 6, pp. S18–S26, 2003. View at Google Scholar · View at Scopus
  22. B. G. Danielson, “Structure, chemistry, and pharmacokinetics of intravenous iron agents,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. S93–S98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Lawrence and M. Helenek, “Development and comparison of iron dextran products,” PDA Journal of Pharmaceutical Science and Technology, vol. 52, no. 5, pp. 190–197, 1998. View at Google Scholar · View at Scopus
  24. R. Fletes, J. M. Lazarus, J. Gage, and G. M. Chertow, “Suspected iron dextran-related adverse drug events in hemodialysis patients,” American Journal of Kidney Diseases, vol. 37, no. 4, pp. 743–749, 2001. View at Google Scholar · View at Scopus
  25. J. T. McCarthy, C. E. Regnier, C. L. Loebertmann, and E. J. Bergstralh, “Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products,” American Journal of Nephrology, vol. 20, no. 6, pp. 455–462, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. B. A. J. Walters and D. B. Van Wyck, “Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients,” Nephrology Dialysis Transplantation, vol. 20, no. 7, pp. 1438–1442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. F. Barish, T. Koch, A. Butcher, D. Morris, and D. B. Bregman, “Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency Anemia: two randomized, controlled trials,” Anemia, vol. 2012, Article ID 172104, 12 pages, 2012. View at Publisher · View at Google Scholar
  28. C. Charytan, M. V. Bernardo, T. Koch, A. Butcher, D. Morris, and D. B. Bregman, “Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study,” Nephrology Dialysis Transplantation, vol. 28, pp. 953–964, 2013. View at Publisher · View at Google Scholar
  29. M. Wolf, T. A. Koch, and D. B. Bregman, “Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women,” Journal of Bone and Mineral Research, vol. 28, no. 8, pp. 1793–1803, 2013. View at Publisher · View at Google Scholar
  30. M. H. Seid, R. J. Derman, J. B. Baker, W. Banach, C. Goldberg, and R. Rogers, “Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial,” American Journal of Obstetrics and Gynecology, vol. 199, no. 4, pp. 435.e1–435.e7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Breymann, F. Gliga, C. Bejenariu, and N. Strizhova, “Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia,” International Journal of Gynecology and Obstetrics, vol. 101, no. 1, pp. 67–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009. View at Publisher · View at Google Scholar · View at Scopus